Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P51460
UPID:
INSL3_HUMAN
Alternative names:
Leydig insulin-like peptide; Relaxin-like factor
Alternative UPACC:
P51460; B4DZ72; G3XAG0; Q3KPI5; Q3KPI6; Q6YNB5; Q9UEA2; Q9UPH6
Background:
Insulin-like 3, also known as Leydig insulin-like peptide or Relaxin-like factor, encoded by the gene with accession number P51460, plays a pivotal role in testicular function. It is implicated as a trophic hormone essential for testicular descent during fetal development and acts as a ligand for the LGR8 receptor.
Therapeutic significance:
Given its crucial role in testicular development, Insulin-like 3 is linked to Cryptorchidism, a common congenital abnormality affecting 2-5% of male births, which can lead to infertility and testicular cancer. Understanding the role of Insulin-like 3 could open doors to potential therapeutic strategies for these conditions.